The test may be able to personalise chemotherapy, preventing patients from potentially going through the harsh treatment for ...

In a pilot programme involving 840 patients with various cancers, the test successfully categorised individuals as either ...

CNS Pharmaceuticals (NASDAQ: CNSP) announced the release of a Virtual Investor KOL Connect segment featuring Dr. Erin Dunbar, Director of Neuro-Oncol ...

Cancer Research UK-funded scientists at the University of Cambridge create a test to predict resistance to chemotherapy. The test uses changes to cancer DNA at diagnosis to predict which patients will ...

Chemotherapy seeks to destroy tumor cells and has been a standard treatment for cancer for decades. However, it doesn't ...

Tens of thousands of cancer patients going through gruelling chemotherapy could have DNA test to predict which form of the ...

Race Oncology Ltd. ( ($AU:RAC) ) has issued an announcement. Race Oncology announced the successful and safe dosing of the first patient with a ...

Watch the “What This Means" segment here HOUSTON, June 18, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ( ...

Detailed price information for Moleculin Biotech CS (MBRX-Q) from The Globe and Mail including charting and trades.

Despite an initial complete remission of 60%-80% in patients receiving anthracycline/cytarabine induction, acute myeloid leukemia (AML) shows a suboptimal long-term outcome rate. Serine/threonine ...